AU2009233429B2 - Oxytocin analogues - Google Patents

Oxytocin analogues Download PDF

Info

Publication number
AU2009233429B2
AU2009233429B2 AU2009233429A AU2009233429A AU2009233429B2 AU 2009233429 B2 AU2009233429 B2 AU 2009233429B2 AU 2009233429 A AU2009233429 A AU 2009233429A AU 2009233429 A AU2009233429 A AU 2009233429A AU 2009233429 B2 AU2009233429 B2 AU 2009233429B2
Authority
AU
Australia
Prior art keywords
asn
leu
gly
gln
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009233429A
Other languages
English (en)
Other versions
AU2009233429A1 (en
Inventor
Sudar Alagarsamy
Robert Galyean
Claudio Schteingart
Kazimierz Wisniewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39722695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009233429(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Publication of AU2009233429A1 publication Critical patent/AU2009233429A1/en
Application granted granted Critical
Publication of AU2009233429B2 publication Critical patent/AU2009233429B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
AU2009233429A 2008-03-31 2009-03-30 Oxytocin analogues Active AU2009233429B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4097308P 2008-03-31 2008-03-31
US61/040,973 2008-03-31
EP08251739 2008-05-19
EP08251739.2 2008-05-19
PCT/IB2009/005351 WO2009122285A1 (en) 2008-03-31 2009-03-30 Oxitocin analogues

Publications (2)

Publication Number Publication Date
AU2009233429A1 AU2009233429A1 (en) 2009-10-08
AU2009233429B2 true AU2009233429B2 (en) 2014-02-13

Family

ID=39722695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009233429A Active AU2009233429B2 (en) 2008-03-31 2009-03-30 Oxytocin analogues

Country Status (20)

Country Link
US (1) US8673841B2 (https=)
EP (2) EP2260053B1 (https=)
JP (1) JP5539310B2 (https=)
KR (1) KR101558404B1 (https=)
CN (1) CN101983205B (https=)
AU (1) AU2009233429B2 (https=)
BR (1) BRPI0910345B1 (https=)
CA (1) CA2718148C (https=)
DK (1) DK2260053T3 (https=)
ES (1) ES2488992T3 (https=)
HR (1) HRP20140716T1 (https=)
IL (1) IL208039A (https=)
MX (1) MX2010010743A (https=)
NZ (1) NZ587817A (https=)
PL (1) PL2260053T3 (https=)
PT (1) PT2260053E (https=)
RU (1) RU2496788C2 (https=)
SI (1) SI2260053T1 (https=)
WO (1) WO2009122285A1 (https=)
ZA (1) ZA201006733B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575853B1 (en) 2010-05-25 2016-08-24 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
EP2935312B1 (en) 2012-12-21 2018-08-08 F.Hoffmann-La Roche Ag Peptides as oxytocin agonists
AU2015270723A1 (en) * 2014-06-03 2016-11-17 F. Hoffmann-La Roche Ag Peptides as oxytocin agonists
CR20160562A (es) * 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
ES2970059T3 (es) 2014-09-19 2024-05-24 Ferring Bv Método de tratamiento del síndrome de Prader-Willi
CN106084015B (zh) * 2016-08-25 2020-01-31 成都圣诺生物制药有限公司 一种合成卡贝缩宫素的方法
US20190135859A1 (en) 2017-08-11 2019-05-09 Ferring B.V. Method of manufacturing a pharmaceutical composition
BR112020001832A2 (pt) * 2017-08-11 2020-07-28 Ferring B.V. método de produção de uma composição farmacêuti-ca
CN107628975B (zh) * 2017-09-17 2019-10-29 贵州医科大学 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
TW202031283A (zh) 2018-09-20 2020-09-01 馬克 Ｃ 曼寧 穩定卡貝縮宮素鼻內製劑
JP7390031B2 (ja) * 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用
JP2023500763A (ja) * 2019-11-04 2023-01-11 フェリング ベスローテン フェンノートシャップ 泌乳の改善のためのメロトシンの鼻腔内投与
WO2022026463A1 (en) * 2020-07-27 2022-02-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Oxytocin analogues and methods for using the same
ES3010259T3 (en) 2021-03-26 2025-04-01 Ot4B Treatment of dysphagia
WO2024044633A2 (en) * 2022-08-23 2024-02-29 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Oxytocin derivatives and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
EP1480998B1 (en) * 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRZONKA, Z. et al. J. Med. Chem. 1983), 26(4), 555-559 *

Also Published As

Publication number Publication date
CA2718148C (en) 2017-11-07
NZ587817A (en) 2012-05-25
ES2488992T3 (es) 2014-09-01
IL208039A0 (en) 2010-12-30
HK1146064A1 (en) 2011-05-13
MX2010010743A (es) 2010-11-04
US8673841B2 (en) 2014-03-18
BRPI0910345B1 (pt) 2021-08-17
US20110044905A1 (en) 2011-02-24
EP2260053A1 (en) 2010-12-15
CN101983205B (zh) 2015-08-19
SI2260053T1 (sl) 2014-08-29
KR101558404B1 (ko) 2015-10-08
BRPI0910345A2 (pt) 2015-10-06
CN101983205A (zh) 2011-03-02
DK2260053T3 (da) 2014-06-23
RU2010139634A (ru) 2012-05-10
WO2009122285A8 (en) 2009-12-10
HRP20140716T1 (hr) 2014-08-29
JP2011516460A (ja) 2011-05-26
EP2260053B1 (en) 2014-05-14
AU2009233429A1 (en) 2009-10-08
RU2496788C2 (ru) 2013-10-27
JP5539310B2 (ja) 2014-07-02
ZA201006733B (en) 2011-06-29
EP2626364A1 (en) 2013-08-14
IL208039A (en) 2016-03-31
PL2260053T3 (pl) 2014-11-28
KR20110005705A (ko) 2011-01-18
PT2260053E (pt) 2014-08-29
CA2718148A1 (en) 2009-10-08
WO2009122285A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
AU2009233429B2 (en) Oxytocin analogues
AU2010295294B2 (en) Oxytocin receptor agonists
ES2203823T3 (es) Analogos heptapeptidicos de oxitocina.
US8883965B2 (en) Compounds
HK1146064B (en) Oxytocin analogues
JPS63303999A (ja) バソプレシン拮抗剤
HK1116807B (en) Vasopressin v1a receptor agonists

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SCHTEINGART, CLAUDIO; ALAGARSAMY, SUDAR; WISNIEWSKI, KAZIMIERZ AND GALYEAN, ROBERT

FGA Letters patent sealed or granted (standard patent)